Stocktoria
VERTEX PHARMACEUTICALS INC / MA VRTX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1991-07-24
VERTEX PHARMACEUTICALS INC / MA financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B |
| R&D expense | — | — | — | — | $3.1B |
| SG&A expense | $1.8B | $1.5B | $1.1B | $944.7M | $840.1M |
| Operating income | $4.2B | -$232.9M | $3.8B | $4.3B | $2.8B |
| Income tax | $690.0M | $784.1M | $760.2M | $910.4M | $388.3M |
| Net income | $4.0B | -$535.6M | $3.6B | $3.3B | $2.3B |
| EPS (diluted) | $15.32 | $-2.08 | $13.89 | $12.82 | $9.01 |
| Operating cash flow | $3.6B | -$492.6M | $3.5B | $4.1B | $2.6B |
| Free cash flow | $3.2B | -$790.3M | $3.3B | $3.9B | $2.4B |
| Cash & equivalents | $5.1B | $4.6B | $10.4B | $10.5B | $6.8B |
| Inventory | $1.7B | $1.2B | $738.8M | $460.6M | $353.1M |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B |
| Total liabilities | $7.0B | $6.1B | $5.1B | $4.2B | $3.3B |
| Shareholders' equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B |
Source: SEC EDGAR filings · CIK 0000875320 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.